A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Trial Profile

A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Entinostat (Primary)
  • Indications CNS cancer; Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 02 Jul 2018 Planned primary completion date changed from 31 May 2018 to 30 Apr 2022.
    • 05 Jun 2018 Results (n=20) assessing efficacy and safety presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 25 Apr 2018 According to a Syndax Pharmaceuticals media release, results from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top